# US 2019/0314323 A1 · Reduction of gastrointestinal tract colonisation by campylobacter

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314323 A1
- Document ID: US20190314323A1
- Status: Published application
- Kind: A1
- Application number: 16/266,946
- Filed: 2019-02-04
- Published: 2019-10-17
- Earliest claimed: 2012-02-16
- Assignees: Akeso Biomedical, Inc.
- Applicants: Akeso Biomedical, Inc.
- Inventors: Jafar Mahdavi; Dlawer Ala'Aldeen
- Web page: https://patentgrep.com/patent/US20190314323A1

## CPC

- A61K 31/295: Iron group metal compounds
- A23K 20/111: Aromatic compounds
- A23K 20/142: Amino acids; Derivatives thereof
- A23K 50/75: for poultry
- A61K 31/132: having two or more amino groups, e.g. spermidine, putrescine
- A61K 31/136: having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A61K 31/164: of a carboxylic acid with an aminoalcohol, e.g. ceramides
- A61K 31/191: having two or more hydroxy groups, e.g. gluconic acid
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/335: having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- A61K 31/7008: Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
- A61P 31/04: Antibacterial agents
- C12Q 1/18: Testing for antimicrobial activity of a material
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23K: FODDER
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Campylobacter are the commonest reported bacterial causes of gastroenteritis in the UK and industrialized worlds. This invention relates to a method of preventing or reducing the colonisation of the gastrointestinal tract of an animal with. Accordingly, the present invention provides a method for disinfection of an animal comprising administering to said animal at least one compound that binds to MOMP or FlaA of in an effective amount to reduce the number of Campylobacter present in the gastrointestinal tract of said animal. The present invention also provides a method of preventing or reducing transmission of from one animal to another.

## Claims

### Claim at position 1

1-29. (canceled)

### Claim 30

A composition comprising ferric quinate, complex of a 3,4-dihydroxyphenylalanine or tyrosine with Fe III or a compound with a structure selected from the group consisting of:
in an effective amount to reduce the number of Campylobacter present in the gastrointestinal tract of an animal subject.

### Claim 31 (depends on 30)

The composition of claim 30, wherein the composition is an animal feed, a food supplement, drinking water or drinking water supplement.

### Claim 32 (depends on 30)

The composition of claim 30, wherein the compound is present in a concentration range between 34 to 340 μM.

### Claim 33 (depends on 30)

The composition of claim 30, wherein the compound specifically binds to at least one amino acid residue selected from the group consisting of Arg3S2, Thr268, Lys278, Lys385, Asn258, Leu290, Tyr294, Phe395, Ile337, Arg381, Asp261, and Ser397 of MOMP (SEQ ID NO:1).

### Claim 34 (depends on 33)

The composition of claim 33, wherein the compound specifically binds to at least amino acid residue Thr268 of MOMP (SEQ ID NO.1).

### Claim 35 (depends on 30)

The composition of claim 30, wherein the compound reduces the campylobacter colony forming units in the gastrointestinal tract of the animal by at least 50%.

### Claim 36 (depends on 30)

The composition of claim 30, the Campylobacter is Campylobacter jejuni or Campylobacter coli.

### Claim 37 (depends on 30)

The composition of claim 30, wherein the compound is a complex of Fe III with 3,4-dihydroxyphenylalanine or tyrosine.

### Claim 38 (depends on 30)

The composition of claim 30, wherein the compound is ferric quinate.

### Claim 39 (depends on 30)

A method for treating or reducing Campylobacter colonization in an animal subject comprising administering to the animal, the composition of claim 30.

### Claim 40 (depends on 39)

The method of claim 39, wherein the Campylobacter is Campylobacter jejuni or Campylobacter Coli.

### Claim 41 (depends on 39)

The method of claim 39, wherein the compound is administered orally.

### Claim 42 (depends on 39)

The method of claim 39, wherein the compound specifically binds to at least one amino acid residue selected from the group consisting of Arg3S2 Thr268, Lys278, Lys385, Asn258, Leu290, Tyr294, Phe395, Ile337, Arg381, Asp261, and Ser397 of MOMP (SEQ ID NO:1).

### Claim 43 (depends on 39)

The method of claim 39, wherein the compound specifically binds to at least amino acid residue Thr268 of MOMP (SEQ ID NO.1).

### Claim 44 (depends on 39)

The method of claim 39, wherein the compound reduces the campylobacter colony forming units in the gastrointestinal tract of the animal by at least 50%.

### Claim 45 (depends on 39)

The method of claim 39, wherein the compound is a complex of Fe III with 3,4-dihydroxyphenylalanine or tyrosine.

### Claim 46 (depends on 39)

The method of claim 39, wherein the compound is ferric quinate.

### Claim 47 (depends on 39)

The method of claim 39, wherein the animal is selected from the group consisting of poultry, cattle, sheep, pigs, goats and deer.

### Claim 48 (depends on 47)

The method of claim 47, wherein the poultry is selected from the group consisting of chickens, geese, turkeys and ducks.

### Claim 49 (depends on 30)

The composition of claim 30, wherein the composition is a foodstuff or a food for human consumption selected from the group consisting of a fresh meat product, a processed meat product, a chilled meat product, a frozen meat product or a cooked meat product, wherein the meat product is selected from the group consisting of beef, lamb, pork, duck, chicken, goose, turkey, and rabbit.
